Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
Avadel Pharmaceuticals plc logo

NASDAQ · AVDL

Avadel Pharmaceuticals plc

Healthcare · Drug Manufacturers - Specialty & Generic

$21.64

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 12:44 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.07B
P/E ratio
-708
Dividend yield
0.00%
52-week range
— – —
Volume
35.02M
Avg. volume
2.93M

Price performance

AVDL price history

1M range · 0 trading sessions · Daily adjusted prices

AVDL does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest AVDL news

The latest Smart Investors Daily articles mentioning AVDL.

Stock researchCompany · Overview

AVDL research

Overview

Company profile and research snapshot.

Company profile

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$20.20
Implied upside
—
Analysts
16
AVDL recent ratings
DateFirmRatingTarget
Nov 20, 2025Wells FargoEqual-Weight—
Nov 7, 2025Wells FargoEqual-Weight—
Oct 28, 2025UBSNeutral—
Oct 23, 2025Leerink PartnersMarket Perform—
Oct 23, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 3, 2026

Form 8.3 -Avadel Pharmaceuticals plc

FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing02nd February 2026 2. INTERESTS AND SHORT POSITIONS(11

globenewswire.com · Dec 5, 2025

Announcement relating to despatch of Rule 15 proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By